Saturday, August 29, 2009 10:01:28 PM
Rumors about a likely Teva bid to acquire ViroPharma started driving up the biotech's share price yesterday, but the developer moved swiftly to squelch the buzz.
"It is certainly not the goal of the management team to be acquired at this point. We are looking to build the company," a spokesperson tells Reuters. Rather than looking for a big company to come along and buy it, ViroPharma says its attention is focused on finding new products that it can acquire.
Still, in a week that has seen market gossip about biotech buyouts hitting fever pitch, some of the analysts were left nodding their heads over the logic of a deal. Zacks Investment Research analyst Jason Napodano told Dow Jones that "ViroPharma would be a good acquisition candidate for a company." And Teva has made it clear that it's interested in getting into the specialty drug business in a big way.
For its part, ViroPharma also insists it is not looking for a partner for either Cinryze, its therapy for hereditary angioedema, or its early-stage therapy for bacterial infection.
ILUS Provides an Update on the Binding Term Sheet Signed with Actelis Networks (NASDAQ: ASNS) • ILUS • May 31, 2024 12:52 PM
Element79 Gold To Provide Summary and Update on Active Exploration Program, Community Relations at RMEC on June 4 • ELEM • May 30, 2024 1:18 PM
Branded Legacy Secures Exclusive Extraction Partnership with One of the World's Largest Kava Distributors and Producers • BLEG • May 30, 2024 8:30 AM
ECGI Holdings, Inc. Announces $2 Million Debt-to-Equity Conversion • ECGI • May 30, 2024 8:30 AM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM